Moderna Stock News and Forecast: MRNA shares falls on Pfizer pill news

Moderna stock is sliding after Pfizer knocks it out.
Pfizer releases data on its antiviral pill to combat covid.
MRNA and other vaccine makers see sharp falls on this news.

Ivan Brian FXStreet

Moderna (MRNA) shares shed some 16% on Friday, having already lost nearly 18% on Thursday. Calamitous news for holders of this one, but the meteoric rise for 2021 is still intact as MRNA shares remain up over 126% for 2021 and 227% over the last year. Perhaps a dose of perspective is needed.

Vaccine manufacturers have been under the cosh since Merck (MRK) came out with news of a pill for covid at the start of October, and now Pfizer has followed that up with an antiviral pill of its own. Antiviral treatments are not vaccines, rather they aim to treat people with the actual disease and lower the hospitalization and death rate. A pill is seen as hurting the demand for vaccines going forward.

Moderna (MRNA) stock news

Merck (MRK) as mentioned was first out with news of its antiviral treatment for covid. Merck's tablet is called Molnupiravir, and the company announced on October 1 that the drug reduces the risk of hospitalization or death by approximately 50%. Merck said in the same press release that it planned to seek immediate emergency use authorization for the drug from the US as soon as possible and from other agencies globally. That news was enough to send Moderna shares down over 11%. Just as the stock looked to be stabilizing, Pfizer (PFE) announced on November 5 its own results into an antiviral drug it has been developing. MRNA stock plunged nearly 17% as mentioned on the news.

Moderna (MRNA) stock forecast

The move on Friday cracked the 200-day moving average. This is big news for technical analysis and shows the size of the retracement. Now MRNA is bearish on all time frames. $188.41 is the next target support. This is a strong level. It was tested three times before finally breaking back in November 2020, February 2021 and May 2021.

Once MRNA shares broke above this level they retraced to test it, but buyers once again stepped in. At this $188 level support from volume is also strong. This is where the majority of the volume profile has been and the point of control is at $155.80. The point of control is the price with the highest amount of volume. Now nothing goes down in a straight line forever, so expect some form of consolidation around these recent losses. Retracements to the 200-day at $250 or the gap at $275 should not be too surprising, but the overall trend is lower unless these levels are broken. Once below $188 we can start to look at buying dips again as the volume profile lends itself to some support.

Short-term swing traders may look to buy the dip at current levels and can take some solace from the strongly overbought Relative Strength Index (RSI). Before diving in, we would look for a confirmation signal from the stochastic crossover. Buying dips in something falling at this speed is like trying to catch a falling knife.

MRNA daily chart

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to Premium Sign In

Author

Ivan Brian

FXStreet

Ivan Brian started his career with AIB Bank in corporate finance and then worked for seven years at Baxter. He started as a macro analyst before becoming Head of Research and then CFO.

EUR/USD looks to stabilize near 1.1600 as focus shifts to US data

EUR/USD is looking to stabilize near 1.1600 in the European session on Wednesday as traders breathe a sigh of relief before the top-tier US ADP jobs and ISM Services PMI data. A pause in the US Dollar uptrend helps the pair's recovery, but surging energy prices due to the Iran war will likely remain a drag.

GBP/USD stays weak near 1.3350 as USD preserves gains

GBP/USD stays in the red below 1.3350 in the European session on Wednesday. Escalating conflict in the Middle East keeps the "flight to safety" theme intact, supporting the US Dollar against the Pound Sterling. Traders will take more cues from the US ADP Employment and ISM Services Purchasing Managers Index reports, which are due later on Wednesday.

Gold sticks to intraday gains above $5,150; upside seems limited amid bullish USD

Gold preserves its modest intraday gains through the Asian session on Wednesday and currently trades just above the $5,150 level, up around 1.30% for the day. Investors remain concerned about a prolonged conflict in the Middle East and its impact on the global economy amid an already uncertain environment.

Bitcoin, Ethereum and Ripple struggle for direction as consolidation persists

Bitcoin, Ethereum and Ripple prices trade with a cautious tone at the time of writing on Wednesday as upside momentum continues to fade across the broader crypto market. BTC remains within a parallel channel, ETH struggles below key resistance, while XRP remains fragile within a descending channel. These top three cryptocurrencies by market capitalization continue to struggle to establish a directional bias amid the consolidation phase.

When rates start driving the bus through a war zone

The volatility regime itself is also changing character. EM carry trades thrive in calm markets. They suffocate in environments that resemble Buckaroo Banzai trading conditions, where headlines move faster than models. That is exactly the world investors are now trying to recalibrate to. Euro rate volatility had been remarkably subdued even while equities were wobbling. That stability is now being questioned, and once volatility leaks into rates it rarely stays contained. Indeed, carry trades love calm seas. War turns the ocean into white water.

Solana Price Forecast: SOL consolidation near resistance as ETF inflows offer mild support

Solana price is facing slight rejection as it approaches the upper boundary of the consolidation range at around $88 on Wednesday. Institutional demand is strengthening as spot Exchange Traded Funds recorded two consecutive inflows so far this week.